Document Detail


Sodium oxybate for narcolepsy.
MedLine Citation:
PMID:  16893342     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sodium oxybate (Xyrem), also known as gamma-hydroxybutyric acid, is the only therapeutic specifically approved in the USA for the treatment of cataplexy in narcolepsy. The US FDA has recently expanded its indication to include excessive daytime sleepiness associated with narcolepsy. In contrast to the antidepressants and stimulants commonly used to treat the disorder, sodium oxybate is the only compound that addresses both sets of symptoms and, when used properly, is less likely to lead to the development of tolerance and other undesirable side effects. In this review, the results of clinical trials and the place of sodium oxybate in narcolepsy treatment are discussed.
Authors:
Martin B Scharf
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of neurotherapeutics     Volume:  6     ISSN:  1744-8360     ISO Abbreviation:  Expert Rev Neurother     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-08     Completed Date:  2006-09-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101129944     Medline TA:  Expert Rev Neurother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1139-46     Citation Subset:  IM    
Affiliation:
The Center for Research in Sleep Disorders, 1275 Kemper Road Cincinnati, OH 45246-3901, USA. mscharf@tristatesleep.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anesthetics, Intravenous / therapeutic use
Cataplexy / drug therapy
Europe / epidemiology
Humans
Incidence
Narcolepsy / diagnosis,  drug therapy*,  epidemiology,  physiopathology
Sodium Oxybate / therapeutic use*
United States / epidemiology
Chemical
Reg. No./Substance:
0/Anesthetics, Intravenous; 502-85-2/Sodium Oxybate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ziprasidone: efficacy and safety in patients with bipolar disorder.
Next Document:  Migraine preventive therapy: selection of appropriate patients and general principles of management.